Abstract:Objective To investigate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in the treatment of retinopathy of prematurity (ROP) and the risk factors for recurrence. Methods A retrospective analysis was performed on the medical data of 159 infants with ROP who were born in the First Affiliated Hospital of Zhengzhou University and underwent anti-VEGF treatment from January 2016 to December 2021. According to the presence or absence of recurrence within the follow-up period after initial anti-VEGF treatment, they were divided into a recurrence group with 24 infants and a non-recurrence group with 135 infants. The medical data were compared between the two groups, and a multivariate logistic regression analysis was used to investigate the risk factors for the recurrence of ROP after anti-VEGF treatment. Results After one-time anti-VEGF treatment, all 159 infants showed regression of plus disease. Recurrence was observed in 24 infants (15.1%) after anti-VEGF treatment, with a mean interval of (8.4±2.6) weeks from treatment to recurrence. The multivariate logistic regression analysis showed that preoperative fundus hemorrhage and prolonged total oxygen supply time were risk factors for the recurrence of ROP (P<0.05), while gestational hypertension was a protective factor (P<0.05). Conclusions Intravitreal anti-VEGF injection is effective for ROP. Preoperative fundus hemorrhage and long duration of oxygen therapy may increase the risk of ROP recurrence, and further studies are needed to investigate the influence of gestational hypertension on the recurrence of ROP.
HAO Qing-Fei,CHEN Jing,RUAN Peng et al. Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity[J]. CJCP, 2022, 24(11): 1207-1212.
Blencowe H, Lawn JE, Vazquez T, et al. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010[J]. Pediatr Res, 2013, 74(Suppl 1): 35-49. PMID: 24366462. PMCID: PMC3873709. DOI: 10.1038/pr.2013.205.
Palmer EA, Hardy RJ, Dobson V, et al. 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity[J]. Arch Ophthalmol, 2005, 123(3): 311-318. PMID: 15767472. DOI: 10.1001/archopht.123.3.311.
Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity[J]. Ophthalmic Surg Lasers Imaging, 2007, 38(3): 233-237. PMID: 17552391. DOI: 10.3928/15428877-20070501-09.
Süren E, ?zkaya D, ?etinkaya E, et al. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment[J]. Int Ophthalmol, 2022, 42(6): 1905-1913. PMID: 35094229. DOI: 10.1007/s10792-021-02188-z.
Gangwe AB, Agrawal D, Gangrade AK, et al. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity[J]. Indian J Ophthalmol, 2021, 69(8): 2171-2176. PMID: 34304203. PMCID: PMC8482928. DOI: 10.4103/ijo.IJO_3016_20.
Sankar MJ, Sankar J, Mehta M, et al. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity[J]. Cochrane Database Syst Rev, 2016, 2: CD009734. PMID: 26932750. DOI: 10.1002/14651858.CD009734.pub2.
Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors[J]. Ophthalmology, 2017, 124(8): 1156-1164. PMID: 28412066. DOI: 10.1016/j.ophtha.2017.03.018.
Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition[J]. Ophthalmology, 2021, 128(10): e51-e68. PMID: 34247850. DOI: 10.1016/j.ophtha.2021.05.031.
Good WV, Hardy RJ, Dobson V, et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study[J]. Pediatrics, 2005, 116(1): 15-23. PMID: 15995025. DOI: 10.1542/peds.2004-1413.
Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs[J]. Pediatrics, 2005, 115(5): e518-e525. PMID: 15805336. DOI: 10.1542/peds.2004-1180.
Ling KP, Liao PJ, Wang NK, et al. Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy[J]. Retina, 2020, 40(9): 1793-1803. PMID: 31800460. DOI: 10.1097/IAE.0000000000002663.
Fadakar K, Mehrabi Bahar M, Riazi-Esfahani H, et al. Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence[J]. Int Ophthalmol, 2022, 42(7): 2017-2028. PMID: 35059928. DOI: 10.1007/s10792-021-02198-x.
Yu CW, Popovic MM, Dhoot AS, et al. Demographic risk factors of retinopathy of prematurity: a systematic review of population-based studies[J]. Neonatology, 2022, 119(2): 151-163. PMID: 35124682. DOI: 10.1159/000519635.
Slidsborg C, Jensen A, Forman JL, et al. Neonatal risk factors for treatment-demanding retinopathy of prematurity: a Danish national study[J]. Ophthalmology, 2016, 123(4): 796-803. PMID: 26854038. DOI: 10.1016/j.ophtha.2015.12.019.
Lyu J, Zhang Q, Chen CL, et al. Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors[J]. Invest Ophthalmol Vis Sci, 2017, 58(3): 1719-1725. PMID: 28324112. DOI: 10.1167/iovs.16-20680.
Tong Q, Yin H, Zhao M, et al. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab[J]. BMC Ophthalmol, 2018, 18(1): 150. PMID: 29940900. PMCID: PMC6019321. DOI: 10.1186/s12886-018-0815-1.
Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins[J]. Proc Natl Acad Sci U S A, 1995, 92(23): 10457-10461. PMID: 7479819. PMCID: PMC40630. DOI: 10.1073/pnas.92.23.10457.
Chen SN, Lian I, Hwang YC, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab[J]. Retina, 2015, 35(4): 667-674. PMID: 25462435. DOI: 10.1097/IAE.0000000000000380.
Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans[J]. Am J Ophthalmol, 2012, 154(4): 682-686.e2. PMID: 22818800. DOI: 10.1016/j.ajo.2012.03.047.